Lundbeck alternatives

Very few large pharma companies limit their entire portfolio to brain disorders. Most competitors maintain broader pipelines across oncology, immunology, or cardiovascular areas while offering some neurology products.

CGRP monoclonal antibodies and oral gepants from Eli Lilly, Amgen, and Teva provide similar preventive options, though dosing frequency, administration route, and regional approvals differ from eptinezumab.

Companies such as Sage Therapeutics and Axsome Therapeutics concentrate on CNS disorders and have launched or late-stage assets for depression and movement disorders, often with novel mechanisms.

Lundbeck actively seeks external innovation through incubators and alliances, whereas bigger players like Pfizer or Novartis typically acquire later-stage assets or run larger internal discovery programs.

In regions without Lundbeck products, clinicians may turn to generic versions from Teva or Sandoz or therapies from regional specialists such as Eisai or UCB that cover overlapping indications.

Biogen and Roche publish extensively on rare neurological conditions through their multiple sclerosis and neuromuscular programs, often with larger trial networks than specialized CNS firms.